174 related articles for article (PubMed ID: 9180912)
1. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group.
McCowage GB; White L; Carpenter P; Lockwood L; Toogood I; Tiedemann K; Shaw PJ
Med Pediatr Oncol; 1997 Aug; 29(2):108-14. PubMed ID: 9180912
[TBL] [Abstract][Full Text] [Related]
2. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group.
Carpenter PA; White L; McCowage GB; Nayanar V; Toogood I; Shaw PJ; Lockwood L; Tiedemann K
Cancer; 1997 Aug; 80(3):489-96. PubMed ID: 9241083
[TBL] [Abstract][Full Text] [Related]
3. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
Marina NM; Shema SJ; Bowman LC; Rodman J; Douglass EC; Furman WL; Pappo A; Santana VM; Hudson M; Meyer WH
Med Pediatr Oncol; 1994; 23(4):328-34. PubMed ID: 8058003
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
[TBL] [Abstract][Full Text] [Related]
5. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
6. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
[TBL] [Abstract][Full Text] [Related]
7. Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group.
White L; McCowage G; Kannourakis G; Nayanar V; Colnan L; Kellie S; Shaw P; Seshadri R; Lockwood L; Tiedemann K
J Clin Oncol; 1994 Mar; 12(3):522-31. PubMed ID: 8120550
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies.
Lydaki E; Bolonaki E; Stiakaki E; Dimitriou H; Kalmantis T; Kalmanti M
Pediatr Hematol Oncol; 1995; 12(6):551-8. PubMed ID: 8589000
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF.
Alvarado Ibarra ML; Borbolla Escoboza JR; López-Hernández MA; González-Avante CM; FloresChapa JD; Trueba Christy E; Anaya Cuellar I
Rev Invest Clin; 1999; 51(2):77-80. PubMed ID: 10410585
[TBL] [Abstract][Full Text] [Related]
10. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human granulocyte-macrophage colony-stimulating factor in children with chemotherapy-induced neutropenia.
Saarinen UM; Hovi L; Riikonen P; Pihkala J; Juvonen E
Med Pediatr Oncol; 1992; 20(6):489-96. PubMed ID: 1435519
[TBL] [Abstract][Full Text] [Related]
12. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
Walewski J; Romejko-Jarosińska J; Zwoliński J; Falkowski S; Siedlecki P
Med Oncol; 1996 Dec; 13(4):199-205. PubMed ID: 9152970
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
[TBL] [Abstract][Full Text] [Related]
15. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
Kritz A; Crown JP; Motzer RJ; Reich LM; Heller G; Moore MP; Hamilton N; Yao TJ; Heelan RT; Schneider JG
Cancer; 1993 Apr; 71(8):2515-21. PubMed ID: 8095854
[TBL] [Abstract][Full Text] [Related]
16. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
Yeung AW; Pang YK; Tsang YC; Wong SW
Cancer; 1994 Apr; 73(7):1960-70. PubMed ID: 7511042
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
Holdsworth MT; Roon R; Ferguson J; Martinez L; Stidley CA; Neidhart JA
Biotechnol Ther; 1993; 4(3-4):183-95. PubMed ID: 8292969
[TBL] [Abstract][Full Text] [Related]
18. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
Michel G; Landman-Parker J; Auclerc MF; Mathey C; Leblanc T; Legall E; Bordigoni P; Lamagnere JP; Demeocq F; Perel Y; Auvrignon A; Berthou C; Bauduer F; Pautard B; Schneider P; Schaison G; Leverger G; Baruchel A
J Clin Oncol; 2000 Apr; 18(7):1517-24. PubMed ID: 10735900
[TBL] [Abstract][Full Text] [Related]
19. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
